The future of the oral pharmacotherapy of male erectile dysfunction: things to come

Bibliography

• KANDEEL FR, KOUSSA VK, SWERDLOFF RS: Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocr. Rev. (2001) 22:342-388.
   PubMed Web of Science ®Google Scholar
• AYTA IA, MCKINLAY, JB, KRANE RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. Br. J. Urol. (1999) 84:50-56.
   Google Scholar
• HOLMQUIST F, STIEF CG, JONAS U, ANDERSSON KE: Effects of the nitric oxide synthase inhibitorNG-nitro-l-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physiol. Scand. (1991) 143:299-304.
   PubMedGoogle Scholar
• HOLMQUIST F, HEDLUND H, ANDERSSON KE: NG-Nitro-l-arginine inhibits non-adrenergic, non-cholinergic relaxation of human isolated corpus cavernosum. Acta Physiol. Scand. (1991) 141:441-442.
   PubMedGoogle Scholar
• IGNARRO LJ, BUSH PA, BUGA GM, WOODS KS, FUKUTO JM, RAJFER J: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Comm. (1990) 170:843-850.
   PubMed Web of Science ®Google Scholar
• BENDER AT, BEAVO JA: Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. (2006) 58:488-520.
   PubMed Web of Science ®Google Scholar
• ROTELLA P: Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. (2002) 1:674-682.
   PubMed Web of Science ®Google Scholar
• FRANCIS SH, CORBIN JD: Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin. Drug Metab. Toxicol. (2005) 1:283-293.
   PubMedGoogle Scholar
• SOMMER F: Potency and selectivity of vardenafil: a phosphodiesterase type 5 inhibitor. Expert Opin. Drug Metab. Toxicol. (2005) 1:295-301.
   PubMedGoogle Scholar
• EARDLY I, CARTLEDGE J: Tadalafil (CIALIS) for men with erectile dysfunction. Int. J. Clin. Pract. (2002) 56:300-304.
   PubMed Web of Science ®Google Scholar
• KANG KK, YU JY, YOO M, KWON JW: The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int. J. Impot. Res. (2005) 17:409-416.
   PubMed Web of Science ®Google Scholar
• PORST H: The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J. Urol. (1996) 155:802-815.
   PubMed Web of Science ®Google Scholar
• OTTENSEN B, WAGNER G, VIRAG R, FAHRENKRUG J: Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br. J. Med. (1984) 288:9-11.
   PubMed Web of Science ®Google Scholar
• CAHN D, MELMAN A, VALCIC M, CHRIST GJ: Forskolin: a promising new adjunct to intracavernous pharmacotherapy. J. Urol. (1997) 155:1789-1794.
   Web of Science ®Google Scholar
• KÜTHE A, WIEDENROTH A, MÄGERT HJ et al.: Expression of different phosphodiesterase genes in human cavernous smooth muscle. J. Urol. (2001) 165:280-283.
   PubMed Web of Science ®Google Scholar
• TAHER A, STIEF CG, RAIDA M, JONAS U, FORSSMANN WG: Cyclic nucleotide phosphodiesterase activity in human cavernous smooth muscle and the effect of various selective inhibitors. Int. J. Impot. Res. (1992) 4(Suppl. 2):11.
   Web of Science ®Google Scholar
• ÜCKERT S, HEDLUND P, WALDKIRCH E et al.: Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone. World J. Urol. (2004) 22:261-266.
   PubMed Web of Science ®Google Scholar
• GUAY D, HAMEL P, BLOUIN M, BRIDEAU C et al.: Discovery of L-791.943: a potent, selective, non-emetic and orally active phosphodiesterase 4 inhibitor. Bioorg. Med. Chem. Lett. (2002) 12:1457-1461.
   PubMed Web of Science ®Google Scholar
• SILVER PJ, DUNDORE RL, BODE DC et al.: Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. (1997) 271:1143-1149.
   Google Scholar
• LAL S: Apomorphine in the evaluation of dopaminergic function in man. Prog. Neuropsychopharmacol. Biol. Psychiatry (1988) 12:117-164.
   PubMed Web of Science ®Google Scholar
• BUVAT J, MONTORSI F: Safety and tolerability of apomorphine SL in patients with erectile dysfunction. BJU Int. (2001) 88(Suppl. 3):30-35.
   PubMedGoogle Scholar
• BUJIS RM: Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Cell Tissue. Res. (1978) 192:423-435.
   PubMed Web of Science ®Google Scholar
• MELIS MR, ARGIOLAS A: Nitric oxide synthase inhibitors prevent apomorphine- and oxytocin-induced penile erection and yawning in male rats. Brain Res. Bull. (1993) 32:71-74.
   PubMed Web of Science ®Google Scholar
• STIEF CG, PADLEY RJ, PERDOK RJ, SLEEP DJ: Cross-study review of the clinical efficacy of apomorphine SL 2 and 3 mg: pooled data from the three placebo-controlled, fixed-dose crossover studies. Eur. Urol. (2002) 1(Suppl. 3):12-20.
   PubMed Web of Science ®Google Scholar
• COWART M, LATSHAW SP, BHATIA P et al.: Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction. J. Med. Chem. (2004) 47:3853-3864.
   PubMed Web of Science ®Google Scholar
• BRIONI JD, MORELAND RB, COWART M et al.: Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc. Natl. Acad. Sci. USA (2004) 101:6758-6763.
   PubMed Web of Science ®Google Scholar
• ENGUEHARD-GUEIFFIER C, HUBNER H, EL HAKMAOUI A et al.: 2-[(4-Phenylpiperazin-1-yl)methyl]-imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl) piperazin-1-ylmethyl]-imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist. J. Med. Chem. (2006) 49:3938-3947.
   PubMed Web of Science ®Google Scholar
• DENNINGER JW, MARLETTA MA: Guanylate cyclase and the NO/cGMP signalling pathway. Biochim. Biophys. Acta (1999) 1411:334-350.
   PubMed Web of Science ®Google Scholar
• LEE YC, MARTIN E, MURAD F: Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. Proc. Natl. Acad. Sci. USA (2000) 97:10763-10768.
   PubMed Web of Science ®Google Scholar
• HOBBS AJ: Soluble guanylate cyclase: an old therapeutic target re-visited. Br. J. Pharmacol. (2002) 136:637-640.
   PubMed Web of Science ®Google Scholar
• FRIEBE A, MÜLLERSHAUSEN F, SMOLENSKI A, WALTER U, SCHULTZ G, KOESLING D: YC-1 potentiates nitric oxide- and carbon monoxide-induced cGMP effects in human platelets. Mol. Pharmacol. (1998) 54:962-967.
   PubMed Web of Science ®Google Scholar
• MIZUSAWA H, HEDLUND P, BRIONI JD, SULLIVAN JP, ANDERSSON KE: Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J. Urol. (2002) 167:2276-2281.
   PubMed Web of Science ®Google Scholar
• NAKANE M, HSIEH G, MILLER LN et al.: Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int. J. Impot. Res. (2002) 14:121-127.
   PubMed Web of Science ®Google Scholar
• BISCHOFF E, SCHRAMM M, STRAUB A, FEURER A, STASCH JP: BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide dependent penile erection. Urology (2003) 61:464-467.
   PubMed Web of Science ®Google Scholar
• STRAUB A, STASCH JP, ALONSO-ALIJA C et al.: NO-independent stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. Lett. (2001) 11:781-784.
   PubMed Web of Science ®Google Scholar
• STASCH JP, DEMBOWSKY K, PERZBORN E, STAHL E, SCHRAMM M: Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br. J. Pharmacol. (2002) 135:344-355.
   PubMed Web of Science ®Google Scholar
• STASCH JP, ALONSO-ALIJA C, APELER H et al.: Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br. J. Pharmacol. (2002) 135:333-343.
   PubMed Web of Science ®Google Scholar
• MORELAND RB, HSIEH GC, NAKANE M et al.: Novel soluble guanylate cyclase activators A-344905and A-305619 activate sGC in vitro and facilitate penile erection in rats.J. Urol. (2002) 167(Suppl. 4):S938.
   Web of Science ®Google Scholar
• MILLER LN, NAKANE M, HSIEH GC et al.: A-350619: a novel activator of soluble guanylyl cyclase. Life Sci. (2003) 72:1015-1025.
   PubMed Web of Science ®Google Scholar
• SEIDLER M, ÜCKERT S, WALDKIRCH E et al.: In vitro effects of a novel class of nitric oxide (NO)-donating compounds on isolated human erectile tissue. Eur. Urol. (2002) 42:523-528.
   PubMed Web of Science ®Google Scholar
• RIFFAUD JP, BERNARBE J, GIULIANO F, JONES R, JEREMY J: Pharmacological profile of sildenafil nitrate (NCX 911) in various models of penile erection. Inflamm. Res. (2001) 50(Suppl. 3):S84.
   PubMed Web of Science ®Google Scholar
• KUENSCH E, REINERS K, MÜLLER-MATTHEIS V, STROHMEYER T, ACKERMANN R, FREUND HJ: Neurological risk profile in organic erectile dysfunction. J. Neurol. Neurosurg. Psych. (1992) 55:275-281.
   PubMed Web of Science ®Google Scholar
• BECKER AJ, ÜCKERT S, STIEF CG et al.: Cavernous and systemic plasma levels of norepinephrine and epinephrine during different penile conditions in healthy males and patients with erectile dysfunction. Urology (2002) 59:281-286.
   PubMed Web of Science ®Google Scholar
• WAGNER G, LACY S, LEWIS R, ZORGNIOTTI A: Buccal phentolamine – a pilot trial for male erectile dysfunction at three separate clinics. Int. J. Impot. Res. (1994) 6(Suppl. 1):D78.
   Google Scholar
• TRAISH A, GUPTA S, GALLANT C, HUANG YH, GOLDSTEIN I: Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms. Int. J. Impot. Res. (1998) 10:215-223.
   PubMed Web of Science ®Google Scholar
• BECKER AJ, STIEF CG, MACHTENS S et al.: Oral phentolamine as treatment for erectile dysfunction. J. Urol. (1998) 159:1214-1216.
   PubMed Web of Science ®Google Scholar
• SOMLYO AP, SOMLYO AV: Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J. Physiol. (2000) 522:177-185.
   PubMed Web of Science ®Google Scholar
• WETTSCHUREK N, OFFERMANNS S: Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J. Mol. Med. (2002) 80:629-638.
   PubMed Web of Science ®Google Scholar
• ETO M, KOZAI T, COSENTINO F, JOCH H, LUSCHER TF: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation (2002)105:1756-1759.
   PubMed Web of Science ®Google Scholar
• REES RW, ZIESSEN T, RALPH DJ, KELL P, MONCADA S, CELLEK S: Human and rabbit cavernosal smooth muscle express Rho-kinase. Int. J. Impot. Res. (2002) 14:1-7.
   PubMed Web of Science ®Google Scholar
• REES P, RALPH DJ, ROYLE M, MONCADA S, CELLEK S: Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile cavernosum. Br. J. Pharmacol. (2001) 133:455-458.
   PubMed Web of Science ®Google Scholar
• CHANG S, HYPOLITE JA, CHANGOLKAR A, WEIN AJ, CHACKO S, DISANTO ME: Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int. J. Impot. Res. (2003) 15:53-62.
   PubMed Web of Science ®Google Scholar
• PARK K, KIM SW, RHU KS, PAICK JS: Chronic administration of an oral rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model. J. Sex. Med. (2006) 3:996-1003.
   PubMed Web of Science ®Google Scholar
• CHITALEY K, WEBB R, MILLS TM: Rho A/Rho-kinase: a novel player in the regulation of penile erection. Int. J. Impot. Res. (2001) 13:67-72.
   PubMed Web of Science ®Google Scholar
• LAU DH, KOMMU S, MUMTAZ FH, MORGAN RJ, THOMPSON CS, MIKHAILIDIS DP: The management of phosphodiesterase-5 (PDE5) inhibitor failure. Curr. Vasc. Pharmacol. (2006) 4:89-93.
   PubMedGoogle Scholar
• WILKES N, WHITE S, STEIN P, BERNIE J, RAJASEKARAN M: Phosphodiesterase-5 inhibition synergizes Rho-kinase antagonism and enhances erectile response in male hypertensive rats. Int. J. Impot. Res. (2004) 16:187-194.
   PubMed Web of Science ®Google Scholar
• PENSON DF, NG C, RAJFER J, GONZALES-CAVIDAD NF: Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology (1997) 138:3925-3932.
   PubMed Web of Science ®Google Scholar
• VERGONI AV, BERTOLINI P, MUTULIS F, WIKBERG JE, SCHIOTH HB: Differential influence of a selective melanocortinMC4 receptor antagonist (HS014) on melanocortin-induced behavioural effects in rats. Eur. J. Pharmacol. (1998) 362:95-101.
   PubMed Web of Science ®Google Scholar
• BRETTO LA, GORZALKA BB: Melatonin enhances sexual behaviour in the male rat. Physiol. Behav. (2000)68:483-486.
   PubMed Web of Science ®Google Scholar
• MOUNTJOY KG, ROBBINS LS, MORTRUD MT, CONE RD: The cloning of a familiy of genes that encode the melanocortin receptors. Science (1992) 257:1248-1251.
   PubMed Web of Science ®Google Scholar
• VAN DER KRAAN M, ADAN RA, ENTWISTLE ML, GISPEN WH, BURBACH JP, TATRO JB: Expression of melanocortin-5 receptor in secretory epithelia supports a functional role in exocrine and endocrine glands. Endocrinology (1998) 139:2348-2355.
   PubMed Web of Science ®Google Scholar
• WESSELLS H, FUCIURELLI K, HANSEN J et al.: Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: a double-blind, placebo-controlled crossover study. J. Urol. (1998) 160:389-393.
   PubMed Web of Science ®Google Scholar
• WESSELLS H, LEVINE N, HADLEY ME, DORR R, HRUBY VJ: Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with melanotan II. Int. J. Impot. Res. (2000) 12(Suppl. 4):S74-S79.
   PubMed Web of Science ®Google Scholar
• DIAMOND LE, EARLE DC, ROSEN RC, WILLETT MS, MOLINOFF PB: Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasalPT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int. J. Impot. Res. (2004) 16:51-59.
   PubMed Web of Science ®Google Scholar
• ROSEN RC, DIAMOND LE, EARLE DC, SHADIACK AM, MOLINOFF PB: Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to VIAGRA. Int. J. Impot. Res. (2004) 162:135-142.
   Google Scholar
• MINER JN, CHANG W, CHAPMAN MS et al.: An orally-active selective androgen receptor modulator is efficacious on bone, muscle and sex function with reduced impact on prostate. Endocrinology (2006) (In Press).
   PubMedGoogle Scholar
• ALBRECHT-BETANCOURT M, HIJAZI RA, CUNNINGHAM GR: Androgen replacement in men with hypogonadism and erectile dysfunction. Endocrine (2004) 23:143-148.
   PubMed Web of Science ®Google Scholar
• HULL KL, HARVEY S: Growth hormone: a reproductive endocrine-paracrine regulator. Rev. Reprod. (2000) 5:175-182.
   PubMedGoogle Scholar
• JUUL A, ANDERSSON AM, PEDERSEN SA et al.: Effects of growth hormone replacement therapy on IGF-related parameters and on pituitary-gonadal axis in GH-deficient males. A double-blind, placebo-controlled crossover study. Horm. Res. (1998) 49:269-278.
   PubMed Web of Science ®Google Scholar
• JUNG GW, SPENCER EM, LUE TF: Growth hormone enhances regeneration of nitric oxide synthase-containing penile nerves after cavernous nerve neurotomy in rats. J. Urol. (1998) 160:1899-1904.
   PubMed Web of Science ®Google Scholar
• BÖGER RH, SKAMIRA C, BODE-BÖGER SM, BRABANT EG, VON ZUR MÜHLEN A, FRÖLICH JC: Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J. Clin. Invest. (1996) 98:2706-2713.
   PubMed Web of Science ®Google Scholar
• BECKER AJ, ÜCKERT S, STIEF CG et al.: Possible role of human growth hormone in penile erection. J. Urol.(2000) 164:2138-2142.
   PubMed Web of Science ®Google Scholar
• NESS BO, ÜCKERT S, SEIDLER M et al.: Mechanism of action of human growth hormone (GH) on isolated human penile erectile tissue. J. Urol. (2005) 173(Suppl. 4):291 (Abstract).
   Google Scholar
• BECKER AJ, ÜCKERT S, STIEF CG et al.: Serum levels of human growth hormone during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology (2002) 59:609-614.
   PubMed Web of Science ®Google Scholar
• BECKER AJ, ÜCKERT S, STIEF CG, JONAS U: Growth hormone, somatomedins and men's health. Aging Male (2002) 5:258-262.
   PubMedGoogle Scholar
• RUDMAN D, FELLER AG, NAGRAJ HS et al.: Effects of growth hormone in men over 60 years old. N. Engl. J. Med. (1990) 323:1-6.
   PubMed Web of Science ®Google Scholar
• PAPADAKIS MA, GRADY D, BLACK D et al.: Growth hormone replacement in older men improves body composition but not functional ability. Ann. Intern. Med. (1996) 124:708-716.
   PubMed Web of Science ®Google Scholar
• JEFFCOATE W: Can growth hormone therapy cause diabetes? Lancet (2000) 355:589-590.
   PubMed Web of Science ®Google Scholar
• CHAN JM, STAMPFER MJ, GIOVANNUCCI E et al.: Plasma insulin-like growth factor 1 and prostate cancer risk: a prospective study. Science (1998) 279:563-566.
   PubMed Web of Science ®Google Scholar
• SMITH RG, SUN Y, BETANCOURT L, ASNICAR M: Growth hormone secretagogues: prospects and potential pitfalls. Best. Pract. Res. Clin. Endocrinol. Metab. (2004) 18:333-347.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD JW, LEE GP, GHARAGOZLOO P et al.: 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors. J. Med. Chem. (2005) 48:1237-1243.
   PubMed Web of Science ®Google Scholar
• HO GD, SILVERMAN L, BERCOVICI A et al.: Synthesis and evaluation of potent and selective cGMP-phosphodiesterase inhibitors. Bioorg. Med. Chem. Lett. (1999) 9:7-12.
   PubMed Web of Science ®Google Scholar